Cushing’s Disease Research Highlights: ENDO 2023
Lisa Machtigall, MD, highlights the latest clinical research about Cushing’s disease from ENDO 2023 in this 30 min CE program.
Lisa Machtigall, MD, highlights the latest clinical research about Cushing’s disease from ENDO 2023 in this 30 min CE program.
Dyikanov et al. developed a machine learning platform that uses a simple blood test to reveal cellular compositions reflective of a person’s immune system. These compositions,…
A suspicious spot on your nipple or the surrounding breast can cause alarm. Learn what it likely is—and what you can do about it.
Preventing the feedback induction of TREX1 downstream of tumor cell STING results in robust interferon signaling and can render cancer cells vulnerable to NK and…
On May 15, 2024, the FDA granted accelerated approval to lisocabtagene maraleucel (Breyanzi, Juno Therapeutics, Inc.) for adults with follicular lymphoma.
Drugmakers are expanding their attack on KRAS mutations, with clinical trials now underway for therapies targeting the common G12D variant, as well as broader pan-RAS…
Fuzuloparib, with or without apatinib, improved PFS over chemotherapy in patients with previously treated, HER2-negative, BRCA-mutated breast cancer.
A retrospective analysis determined the association between various adverse effects and overall and progression-free survival in patients with HCC receiving atezolizumab plus bevacizumab.
More than 150 team members will staff the new facility when it opens in January.
Atezolizumab plus chemotherapy did not improve OS vs chemotherapy alone in select patients with early relapsing triple-negative breast cancer.